Patents by Inventor Xavier de Mollerat du Jeu
Xavier de Mollerat du Jeu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11872285Abstract: The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications.Type: GrantFiled: October 5, 2020Date of Patent: January 16, 2024Assignee: Life Technologies CorporationInventors: Xavier de Mollerat du Jeu, Nektaria Andronikou
-
Patent number: 11690921Abstract: Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.Type: GrantFiled: May 15, 2019Date of Patent: July 4, 2023Assignees: Sangamo Therapeutics, Inc., Life Technologies CorporationInventors: Anthony Conway, Xavier de Mollerat du Jeu, Shikha Mishra
-
Publication number: 20230193214Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.Type: ApplicationFiled: February 13, 2023Publication date: June 22, 2023Inventors: Xin YU, Xavier de MOLLERAT du JEU, Chao Yan Lin, Jian Liu, Jonathan Zmuda
-
Publication number: 20230181742Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.Type: ApplicationFiled: August 19, 2022Publication date: June 15, 2023Inventors: Zhiwei Yang, Parul Angrish, Xavier de Mollerat Du Jeu, Kristin Wiederholt
-
Patent number: 11608491Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.Type: GrantFiled: February 21, 2020Date of Patent: March 21, 2023Assignee: Life Technologies CorporationInventors: Xin Yu, Xavier de Mollerat du Jeu, Chao Yan Liu, Jian Liu, Jonathan Zmuda
-
Publication number: 20220348964Abstract: A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.Type: ApplicationFiled: July 8, 2022Publication date: November 3, 2022Inventors: Xin YU, Xavier de MOLLERAT du JEU
-
Patent number: 11464863Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.Type: GrantFiled: August 30, 2019Date of Patent: October 11, 2022Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Zhiwei Yang, Parul Angrish, Xavier de Mollerat du Jeu, Kristin Wiederholt
-
Patent number: 11414675Abstract: A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.Type: GrantFiled: September 29, 2017Date of Patent: August 16, 2022Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Xin Yu, Xavier de Mollerat du Jeu
-
Publication number: 20220001023Abstract: Provided herein are, inter alia, compositions and methods useful for the in vivo delivery of bioactive agents (e.g., therapeutic or diagnostic agents). The compositions provided herein include cationic lipids, helper lipids and a biostability enhancing agent, which together form a lipid aggregate with the bioactive agent and allow for the systemic delivery of the bioactive agent to, for example, lung tissue without the requirement for biomolecular targeting.Type: ApplicationFiled: July 16, 2021Publication date: January 6, 2022Inventors: Shikha MISHRA, Xavier de MOLLERAT du JEU
-
Publication number: 20210123009Abstract: The present disclosure provides electroporation cartridges for single use electroporation as well as electroporation cartridges for automated batch processing, electroporation instruments and systems and methods of electroporation using these devices and systems. In some embodiments, electroporation cartridges comprise an electroporation chamber defined by an elongate body, a first electrode at a proximal end and a second electrode at a distal end of a chamber. Electroporation systems of the disclosure include one or more components including a pulse generator, compartments for placing either flow-through or single use electroporation cartridges, components for storage of cells, cooling and pre-cooling mechanisms, removably insertable modular casings having compartments for holding and arranging electroporation system and reagent components, one or more pumps for moving sample through the system, and processors and controllers.Type: ApplicationFiled: October 23, 2020Publication date: April 29, 2021Inventors: Steven Huei YEO, Siu Wee HON, Han WEI, Yvonne PECK, Way Xuang LEE, Benyong SHI, Chee Wai CHAN, Beng Heng (Derrick) LIM, Dhanaraj SHANMUGAM, Stacey TEO, Jun Yan THAM, Kok Shyong CHONG, Li Yang LIM, Michael GORDON, Nektaria ANDRONIKOU, Chris ROSSMANN, Xavier DE Mollerat DU JEU, Ulrich FORKE
-
Publication number: 20210054415Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.Type: ApplicationFiled: November 9, 2020Publication date: February 25, 2021Inventors: Xin YU, Xiquan LIANG, Xavier de MOLLERAT du JEU, Robert Jason POTTER
-
Publication number: 20210023225Abstract: The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications.Type: ApplicationFiled: October 5, 2020Publication date: January 28, 2021Inventors: Xavier de MOLLERAT du JEU, Nektaria ANDRONIKOU
-
Publication number: 20200392537Abstract: The present invention is directed to non-naturally occurring peptides containing a membrane-penetrating amino acid sequence and further at least one polycationic moiety or peptide sequence. The peptides are suitable for use in delivery a cargo to the interior of a cell. Suitable cargo includes nucleic acid molecules (including DNA, RNA or PNA), polypeptides, or other biologically active molecules. The present invention is further directed to transfection complexes containing the non-naturally occurring peptides of the present invention in non-covalent association with at least one cationic lipid and a cargo to be delivered to the interior of a cell. The invention further relates to methods for the preparation and use of the non-naturally occurring peptides for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture, an animal or a human. The invention also relates to compositions and kits useful for transfecting cells.Type: ApplicationFiled: August 28, 2020Publication date: December 17, 2020Inventor: Xavier de MOLLERAT du JEU
-
Patent number: 10829787Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.Type: GrantFiled: October 14, 2016Date of Patent: November 10, 2020Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Xin Yu, Xiquan Liang, Xavier de Mollerat du Jeu, Robert Jason Potter
-
Patent number: 10792362Abstract: The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications.Type: GrantFiled: December 21, 2018Date of Patent: October 6, 2020Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Xavier de Mollerat du Jeu, Nektaria Andronikou
-
Patent number: 10760098Abstract: The present invention is directed to non-naturally occurring peptides containing a membrane-penetrating amino acid sequence and further at least one polycationic moiety or peptide sequence. The peptides are suitable for use in delivery a cargo to the interior of a cell. Suitable cargo includes nucleic acid molecules (including DNA, RNA or PNA), polypeptides, or other biologically active molecules. The present invention is further directed to transfection complexes containing the non-naturally occurring peptides of the present invention in non-covalent association with at least one cationic lipid and a cargo to be delivered to the interior of a cell. The invention further relates to methods for the preparation and use of the non-naturally occurring peptides for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture, an animal or a human. The invention also relates to compositions and kits useful for transfecting cells.Type: GrantFiled: November 13, 2017Date of Patent: September 1, 2020Assignee: LIFE TECHNOLOGIES CORPORATIONInventor: Xavier de Mollerat du Jeu
-
Publication number: 20200270583Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.Type: ApplicationFiled: February 21, 2020Publication date: August 27, 2020Inventors: Xin YU, Xavier de MOLLERAT du JEU, Chao Yan Liu, jJian Liu, Jonathan Zmuda
-
Publication number: 20200061197Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.Type: ApplicationFiled: August 30, 2019Publication date: February 27, 2020Inventors: Zhiwei YANG, Parul ANGRISH, Xavier de MOLLERAT du JEU, Kristin WIEDERHOLT
-
Publication number: 20190365924Abstract: Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.Type: ApplicationFiled: May 15, 2019Publication date: December 5, 2019Inventors: Anthony Conway, Xavier de Mollerat du Jeu, Shikha Mishra
-
Patent number: 10406237Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.Type: GrantFiled: December 15, 2017Date of Patent: September 10, 2019Assignee: LIFE TECHNOLOLGIES CORPORATIONInventors: Zhiwei Yang, Parul Angrish, Xavier de Mollerat du Jeu, Kristin Wiederholt